Form 4: Aldeyra Therapeutics Director Nancy Miller-Rich Granted Over 65,000 Stock Options

Aldeyra Therapeutics, Inc. Director Nancy Miller-Rich was granted 65,141 stock options with an exercise price of $2.685, vesting over one year subject to continued service.

Summary

• Nancy Miller-Rich, a Director of Aldeyra Therapeutics, Inc. (ALDX), was granted a total of 65,141 stock options on June 10, 2025.
• The options have an exercise price of $2.685 per share.
• A grant of 62,728 stock options is exercisable with respect to 100% of the shares on the one-year anniversary of the grant date (June 10, 2026), provided Ms. Miller-Rich provides continuous service as a member of the Board of Directors.
• An additional grant of 2,413 stock options is exercisable with respect to 100% of the shares on the one-year anniversary of the grant date (June 10, 2026), provided she provides continuous service as a member of the Compensation Committee of the Board of Directors.
• All granted options have an expiration date of June 9, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a routine compensation event, generally viewed as a positive for aligning management incentives with shareholder interests, but does not indicate significant operational or financial news that would dramatically alter the company's outlook.

Positives

• The stock option grants align the financial interests of Director Nancy Miller-Rich with those of Aldeyra Therapeutics' shareholders, incentivizing long-term value creation.
• The vesting conditions encourage continued service and commitment from a key board member, ensuring stability in corporate governance.

Negatives

• The exercise of these options in the future could lead to a minor dilution of existing shareholder equity, although this is a standard aspect of equity compensation plans.

Risks

• The vesting of the stock options is contingent upon Nancy Miller-Rich's continuous service as a director and compensation committee member through the one-year anniversary of the grant date.
• The value of the options is dependent on Aldeyra Therapeutics' stock price exceeding the exercise price of $2.685 per share by the time of exercise.

Future Outlook

The stock option grants are forward-looking incentives, designed to ensure the continued service and alignment of Director Nancy Miller-Rich with the company's long-term strategic goals and shareholder value creation.

Industry Context

The granting of stock options to non-employee directors is a common and standard practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors. This compensation structure is widely used to attract and retain qualified board members and to align their interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The structure of this equity grant, including the one-year cliff vesting period and a 10-year term for the options, is consistent with typical compensation practices for non-employee directors in the biotechnology industry.
• Similar to companies like Biogen Inc. or Vertex Pharmaceuticals Inc., equity compensation forms a significant part of director remuneration, aiming to foster long-term commitment and performance alignment.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of stock options from Aldeyra Therapeutics, Inc. to Nancy Miller-Rich, a Director of the company, which is a standard insider transaction for compensation purposes.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from enhanced alignment of director's interests with long-term company performance.
• Employees: No direct impact mentioned, but reflects standard corporate compensation practices.

Next Steps

• The granted stock options will vest on the one-year anniversary of the grant date (June 10, 2026), provided Nancy Miller-Rich continues her service as a director and compensation committee member.

Key Dates

Keywords

Aldeyra Therapeutics, ALDX, Form 4, stock options, insider transaction, director compensation, equity grant, vesting, Nancy Miller-Rich, biotechnology